Showing 20 of 24 recruiting trials for “medullary-thyroid-carcinoma”
Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels
IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers
Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer
Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer
XL092 and Cemiplimab in BRAF WT Thyroid Cancer
👨⚕️ Siddharth Sheth, DO MPH, UNC Lineberger Comprehensive Cancer Center📍 2 sites📅 Started Jun 2025View details ↗
ToPanc Trial: Survival After Total Versus Partial Pancreaticoduodenectomy for Adenocarcinoma of the Pancreatic Head, Distal Cholangiocarcinoma, and Ampullary Cancer
👨⚕️ Anna S Wenning, MD, PhD, Department of Visceral Surgery and Medicine Inselspital, Bern University Hospital📍 7 sites📅 Started May 2025View details ↗
A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma
Sacituzumab govitEcan in THYroid Cancers
👨⚕️ Alejandro García-Alvarez, M.D.; Ph.D., Hospital Universitario Vall d´Hebron📍 11 sites📅 Started Sep 2024View details ↗
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer
Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy
Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer
👨⚕️ Yansong Lin, Ph D, Peking Union Medical College Hospital📍 1 site📅 Started Nov 2023View details ↗
A Study of Avutometinib and Defactinib in People With Thyroid Cancer
👨⚕️ Alan Ho, MD, PhD, Memorial Sloan Kettering Cancer Center📍 7 sites📅 Started Aug 2023View details ↗
RecruitingNCT05994365 ↗
Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma
Individualized Dose Escalation of 5-FU for Gastrointestinal Cancer
👨⚕️ Gabriel A Brooks, M.D., Dartmouth-Hitchcock Medical Center📍 1 site📅 Started Jul 2023View details ↗
Modified vs Conventional Blumgart Anastomosis of LPD for the Effects of Pancreatic Fistula of Periampullary Carcinoma
👨⚕️ Liu Guohua, Affiliated Hospital of Guangdong Medical University📍 1 site📅 Started Jul 2023View details ↗
The ADAPTA Study: ADjuvant chemotherAPy After Curative Intent resecTion of Ampullary Cancer.
👨⚕️ Moh'd Abu Hilal, MD, PhD, Fondazione Poliambulanza Instituto Ospedaliero📍 1 site📅 Started Jul 2023View details ↗
NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)
👨⚕️ Ellen Kapiteijn, MD, PhD, Leiden University Medical Center📍 1 site📅 Started Jan 2023View details ↗
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
👨⚕️ Nadine Abi-Jaoudeh, MD, Chao Family Comprehensive Cancer Center📍 1 site📅 Started Sep 2022View details ↗
Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative Fistula
Page 1 of 2Next →
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →